Can Red Light Actually Lower Blood Sugar? Early Clinical Trials Suggest a Real Signal (Not a Miracle)

Can photobiomodulation (red + near-infrared light) meaningfully improve glycemic control in people with type 2 diabetes? In this Deep Dive, Dr. Mike Belkowski breaks down a 2026 systematic review of randomized clinical trials that tested PBM for diabetes outcomes like fasting glucose, post-prandial glucose, and HbA1c.

The evidence base is small — only 4 RCTs met strict inclusion criteria (control/sham required) — but the signal was generally favorable: PBM was associated with reductions in fasting glucose, post-prandial glucose, and HbA1c, and in some studies improvements in lipid markers. The catch is that overall certainty is very low to low due to small samples, protocol heterogeneity, and bias concerns. Translation: promising adjunct, not proven therapy, and not remotely a replacement for standard care.

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Photobiomodulation Therapy to Improve Glycemic Control in People with Diabetes Mellitus: A Systematic Review

-

Key Quotes From Dr. Mike:

“Type 2 diabetes… chronic hyperglycemia disrupts mitochondrial metabolism, increases oxidative stress, activates inflammatory pathways…”

“PBM, mostly red and near infrared wavelengths, was associated with reductions in fasting glucose, postprandial glucose, and HBA1C.”

“These were longer protocols, 30 minutes per session, 3 sessions per week for 12 weeks.”

“PBM is not a replacement for medication, nutrition, exercise, or medical monitoring.”

“We’re early, but the direction is real.”

-

Key Points

• The review included 4 randomized clinical trials (1993–2025 search; control/sham required).

• Outcomes emphasized fasting glucose, post-prandial glucose, HbA1c, plus some cardiometabolic measures.

• Overall finding: PBM was generally associated with improved glycemic markers, sometimes lipids too.

• Evidence certainty: very low to low (small N, heterogeneity, some risk-of-bias concerns).

• Protocol types:

  • Wrist “watch” PBM over radial pulse area: 30 min, 3x/week, 12 weeks, often alongside meds.

  • LED pad PBM over large tissue regions (limbs/abdomen): crossover, sham-controlled, acute/time-response.

• Dose response looks biphasic (a “sweet spot”): one trial found 100 J sustained lower glycemia up to 12 hours, while higher dose wasn’t clearly better.

• Mechanistic framework: mitochondria/CCO, NO & microcirculation, ROS → Ca²⁺ → AMPK, and GLUT4 translocation.

• Bottom line: PBM is a plausible metabolic signal and an early clinical adjunct candidate—but the field needs larger, standardized RCTs and clearer dose-response mapping.

-

Episode timeline

• 0:19–1:26 — The “futuristic” question + disclaimer (PBM as adjunct, not replacement)

• 1:30–3:20 — Why PBM could matter in T2D (hyperglycemia → mito dysfunction/oxidative stress loop)

• 3:24–4:51 — Systematic review methods + headline result (only 4 RCTs; generally favorable; low certainty)

• 5:04–6:03 — Trial type #1: wrist “watch” PBM over radial pulse (12-week adjunct outcomes)

• 6:03–7:28 — Trial type #2: LED pad PBM over larger tissue areas (crossover; acute/time-response; dose effects)

• 7:28–8:40 — Biphasic response explanation + quality/bias ratings (PEDro, ROB2, GRADE)

• 8:41–10:34 — Mechanisms: bioenergetics, NO/microcirculation, ROS→AMPK, GLUT4

• 10:34–11:58 — Nuance: mixed literature; protocol variability likely drives inconsistent results

• 12:02–13:26 — The Energy Code conclusion: promising adjunct, early evidence, needs standardization

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

BioLight:

Website

Instagram

YouTube

Facebook